Shares of Replimune Group, Inc. (REPL) have gained 2.7% over the past four weeks to close the last trading session at $7.16, but there could still be a solid upside left in the stock if short-term ...

Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members from the Replimune management t ...

Who were the biggest winners on Day 1 of the 2026 NFL Scouting Combine workouts? Did Penn State DT Zane Durant show today ...

The subscription economy helped boost mobile app revenues in 2025, even as app downloads declined for the fifth consecutive year, according to app intelligence firm Appfigures‘ annual report. In 2025, ...

The biotech received the good news it was hoping for from a top national regulator. This concerned RP1, its advanced melanoma drug. Well before market open, Replimune announced that the U.S. Food and ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

OpenAI's Sora, its short-form AI video app, hit 1 million downloads less than five days after its launch, according to an executive. Sora allows users to generate short videos for free by typing in a ...

Hate waiting forever for a big game, software update, or important file to finish downloading? While slow internet might be the culprit, it's not always the only reason. Before blaming your ISP, you ...

Replimune Group’s REPL share price tumbled 54.2% over the past three months. The massive setback was observed after the FDA issued a complete response letter (CRL) in July, against the biologics ...

A crucial meeting with a regulator didn't seem to go well. It was about a leading pipeline drug being developed by the company. The meeting was conducted with U.S. Food and Drug Administration (FDA) ...